EGFR and non-small cell lung carcinoma: Quisinostat restoring E-cadherin expression by inhibiting HDAC activity might increase the sensitivity of NSCLC cells to EGFR inhibitors (Witta et al. 2006), providing a molecular basis for combination therapy in patients with NSCLC.